$BLRX Q3 earnings Monday Nov 23 at 8:30am EST. Expecting cash position update, GLIX1 trial progress, and potentially the long awaited PDAC interim analysis with Regeneron and Columbia.
Phase 1 GBM human data still on track H1 2027.
https://t.co/9QpVhEQhs5
$MRNA $RXRX $ARWR $SLS
@BiopharmIQ $BLRX Q3 earnings Monday Nov 23 at 8:30am EST. Expecting cash position update, GLIX1 trial progress, and potentially the long awaited PDAC interim analysis with Regeneron and Columbia.
Phase 1 GBM human data still on track H1 2027.
https://t.co/9QpVhEPJCx
$MRNA $IONS $SLS
@BiopharmIQ $BLRX Q3 earnings Monday Nov 23 at 8:30am EST. Expecting cash position update, GLIX1 trial progress, and potentially the long awaited PDAC interim analysis with Regeneron and Columbia.
Phase 1 GBM human data still on track H1 2027.
https://t.co/9QpVhEPJCx
$MRNA $IONS $SLS
$BLRX Q3 earnings Monday Nov 23 at 8:30am EST. Expecting cash position update, GLIX1 trial progress, and potentially the long awaited PDAC interim analysis with Regeneron and Columbia.
Phase 1 GBM human data still on track H1 2027.
https://t.co/9QpVhEQhs5
$MRNA $RXRX $ARWR $SLS
@BioLineRx_Ltd enters into $5.6mm royalty monetization transaction w/ Soleus Capital
*Sale of future Aphexda royalties
$BLRX retains rights to future commercial milestone payments
*Proceeds to support GLIX1 development & partial Blackrock loan repayment
*30Nov close
https://t.co/6yETMFEPVy
$BLRX - BioLineRx Q3 earnings expected tomorrow Nov 18. Watching for a PDAC interim update from their Phase 2b pancreatic cancer trial with Columbia University and Regeneron.
91% disease control rate in early pilot data.
$MRNA $RXRX $ARWR $IONS
https://t.co/XIstPsQnwH
$BLRX - BioLineRx Q3 earnings expected tomorrow Nov 18. Watching for a PDAC interim update from their Phase 2b pancreatic cancer trial with Columbia University and Regeneron.
91% disease control rate in early pilot data.
$MRNA $RXRX $ARWR $IONS
https://t.co/XIstPsQnwH
🧬 Biotech Stock News 11/16 @ Open (2 of 2)
$BLRX -1% Phase 1/2a Clinical Study Updates
$MGTX -1% Oral Presentation at ObesityWeek 2026
$TEVA -2% FDA Approves IGALMI for Agitation
$CRBP -2% Phase 1b CANYON-1 Data for CRB-913
$AMLX -2% Results from Phase 3 LUCIDITY Trial
$ACOG -3% Publication of Patent for Benzgalantamine
$NUVB -3% Long-Term Data for Safusidenib
$AKBA -3% Term Loan Facility Worth $140 Million
$ALLR -4% Expands Phase 2 Stenoparib Trial
$INAB -4% Updated Glioblastoma Data with Therapy
$CYTK -4% Prescribing Information for MYQORZO® Expanded
$CORT -4% Response to Relacorilant Plus Nab-Paclitaxel
$VKTX -5% Clinical Data from VK2735 Program
$ENLV -9% Pricing of $7.5 Million Offering
$SMMT -10% Update on Ivonescimab License Application
$ACRS -12% Phase 2b Trial of Modzatinib
$ACRS -12% Phase 2 Results for Bosakitug
$CNSY -16% Interim ReSPECT-LM Data for REYOBIQ™
$HELP -22% Positive Results for HLP003 Study
See image & the reply below for details 👇
$BLRX - @BioLineRx_Ltd Fourth patient cohort now dosing. Zero safety signals. Window-of-opportunity cohorts next to confirm brain penetration in actual human tumor tissue.
Phase 1 GBM data H1 2027. $11M market cap.
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
https://t.co/6tC1lVIITY
$BLRX - @BioLineRx_Ltd Fourth patient cohort now dosing. Zero safety signals. Window-of-opportunity cohorts next to confirm brain penetration in actual human tumor tissue.
Phase 1 GBM data H1 2027. $11M market cap.
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
https://t.co/6tC1lVIITY
$BLRX - @BioLineRx_Ltd Fourth patient cohort now dosing. Zero safety signals. Window-of-opportunity cohorts next to confirm brain penetration in actual human tumor tissue.
Phase 1 GBM data H1 2027. $11M market cap.
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
https://t.co/6tC1lVIITY
$BLRX SNO posters tomorrow in Philadelphia. ESMO data already showed GLIX1 beating monotherapy at low doses in ovarian cancer. PDAC interim with Regeneron still expected before end of 2026.
Phase 1 GBM human data H1 2027.
#ESMO2026 $MRNA $RXRX $ARWR $IONS $NBIS
🎗️ Biopharma Mid-Weekly Recap:
Oncology Highlights from 𝕏
Ahead of #ESMO2026, we’ve picked 15 recent #oncology posts worth a closer look. From pancreatic and lung cancer data to ADC developments, cancer detection, and immunotherapy, here’s what caught our attention 👇
@drrichjlaw
$AZN $SMMT: AstraZeneca’s $2B Investment and Cancer Combination Deal Put Summit in Focus
https://t.co/BlZOoUGbIM
@Stephanie_Link
$NTRA: Signatera MRD Study Links Test Results to Outcomes in More Than 1,100 Lung Cancer Patients
https://t.co/JgaUIlpemg
@semodough
$TNGX $RVMD: Pancreatic Cancer Response Rates in Focus Ahead of the Vopimetostat–Daraxonrasib ESMO Update
https://t.co/hlfWdDC2vN
@kainvests
$IOVA: Iovance’s Upcoming NSCLC Data Take Center Stage in a Look at Lung Cancer Progress
https://t.co/0AwfDKenE1
@tyler_bosserman
$ABCL: Bayer’s Priority Review for Breast Cancer Treatment-Related Hot Flashes Draws Attention to ABCL635
https://t.co/BYXBIWyrZx
@doepke_michel
$VSTM: Verastem Plans Late-Breaking RAMP 201 Ovarian Cancer Biomarker Presentation at IGCS
https://t.co/gD2zSj8k3R
@BreakoutBiotech
$TWST $GRAL: Could Wider Galleri Use Lift Demand for Twist’s Cancer Testing Tools?
https://t.co/WKPOzEJnwT
@bioinvestor24
$ERAS $TNGX $LLY: Oncology Biotechs Draw Investor Enthusiasm and Lilly Takeover Speculation
https://t.co/PHt5SsxoAf
@MarcJacksonLA
$MRK $DSNKY: Merck and Daiichi Withdraw Lung Cancer ADC Filing, Shifting Attention to Rivals
https://t.co/PenDQ4Wxdm
@KatrinaHelle
$SLS $BMY: GPS Immunotherapy’s Potential in AML Maintenance, With Onureg as the Comparison
https://t.co/qNbbmz2GzJ
@DanaFarber
A Rare Inherited EGFR Mutation Could Help Identify Lung Cancer Risk in Never-Smokers
https://t.co/K6NdtWmfHt
@Banana_Oncology
$RVMD: Daraxonrasib Appears in Updated NCCN Guidance for KRAS-Mutant Lung Cancer as an Off-Label Option
https://t.co/qBd93Tm6QU
@WallStSai
$MRK $AMGN: Withdrawal of Merck’s Small Cell Lung Cancer ADC Filing May Give Imdelltra More Room
https://t.co/8K9InSKl4i
@raffcolo
ADCs Make Up 23% of the Late-Breaking Abstracts at ESMO 2026
https://t.co/JMvIjxnuKC
@Wilson_WZW
$IBRX: How Therapeutic Cancer Vaccines Aim to Activate Immunity After Diagnosis
https://t.co/IwEXaFSG4l
@BioLineRx_Ltd- $BLRX SNO posters in 3 days. PDAC interim with Regeneron still expected before end of 2026. Phase 1 GBM human data H1 2027.
$11M market cap with back to back catalysts lined up into next year. 📈
https://t.co/zFMD9sBj6e
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
@BioLineRx_Ltd- $BLRX SNO posters in 3 days. PDAC interim with Regeneron still expected before end of 2026. Phase 1 GBM human data H1 2027.
$11M market cap with back to back catalysts lined up into next year. 📈
https://t.co/zFMD9sBj6e
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
$BLRX GLIX1 just presented at ESMO 2026 showing synergy with PARP inhibitors in HR-proficient ovarian cancer outperforming cisplatin at low doses
Ovarian cancer arm now being added to the Phase 1 trial
$50B market.
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
https://t.co/hSKI86geR2
$BLRX GLIX1 just presented at ESMO 2026 showing synergy with PARP inhibitors in HR-proficient ovarian cancer outperforming cisplatin at low doses
Ovarian cancer arm now being added to the Phase 1 trial
$50B market.
$MRNA $RXRX $ARWR $IONS $NBIS $RCUS
https://t.co/hSKI86geR2